Abstract
RASSF1A, one of the two major isoforms of the putative tumor suppressor gene RASSF1, located at 3p21.3, is inactivated in a variety of human cancers including lung, breast, bladder and renal cell carcinomas. We have isolated and cloned two human homologues of this gene, RASSF3 and NORE1, located at 12q14.1 and 1q32.1, respectively. Both RASSF3 and NORE1 share almost 60% homology, at the amino acid level, with RASSF1. The RASSF3 gene contains five exons and encodes a 247 amino acid protein (MW of 28.6 kDa) with a highly conserved Ras association (RalGDS/AF-6) (RA) domain at the C-terminus. RASSF3 is ubiquitously expressed in all normal tissues and cancer cell lines analysed. NORE1, which is homologous to the previously described mouse Nore1 gene, exists in at least two spliced isoforms, A and B. Transcript A encodes a protein of 418 amino acids (MW or 47 kDa) while transcript B contains an ORF of 265 aa (MW of 30.5 kDa). Both share a RA domain, encoded by exons 3 through 6. NORE1A and NORE1B are expressed in most of the normal tissues analysed but they appear to be down-regulated in several cancer cell lines. However, contrary to RASSF1A, gene silencing by methylation of the CpG islands at which the two NORE1 transcripts initiate is not a common event in human primary tumors. RASSF3 and NORE1B are very similar, at the N-terminus, to the splice variant C of RASSF1 (RASSF1C), which does not seem to be involved in tumorigenesis. NORE1A is most closely related to RASSF1A, for sequence homology and genomic organization. However, aberrations in tumors have so far not been found. The presence of a Ras association domain common to NORE1, RASSF1, and RASSF3 suggests their possible involvement in Ras-like signaling pathways.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Adjei AA . 2001 J. Natl. Cancer Inst. 93: 1062–1074
Agathanggelou A, Honorio S, Macartney DP, Martinez A, Dallol A, Rader J, Fullwood P, Chauhan A, Walker R, Shaw JA, Hosoe S, Lerman MI, Minna JD, Maher ER, Latif F . 2001 Oncogene 20: 1509–1518
Almeida A, Zhu XX, Vogt N, Tyagi R, Muleris M, Dutrillaux AM, Dutrillaux B, Ross D, Malfoy B, Hanash S . 1998 Oncogene 16: 2997–3002
Avruch J, Khokhlatchev A, Kyriakis JM, Luo Z, Tzivion G, Vavvas D, Zhang XF . 2001 Recent Prog. Horm. Res. 56: 127–155
Bar-Sagi D . 2001 Mol. Cell. Biol. 21: 1441–1443
Bar-Sagi D, Hall A . 2000 Cell 103: 227–238
Baylin SB, Herman JG . 2000 Trends Genet. 16: 168–174
Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP . 1998 Adv. Cancer Res. 72: 141–196
Bos JL . 1989 Cancer Res. 49: 4682–4689
Bos JL . 1998 EMBO J. 17: 6776–6782
Burbee DG, Forgacs E, Zöcgbayer-Müller S, Shivakumar L, Fong K, Gao B, Randle D, Kondo M, Virmani A, Bader S, Sekido Y, Latif F, Milchgrub S, Toyooka S, Gazdar AF, Lerman MI, Zabarovsky E, White M, Minna JD . 2001 J. Natl. Cancer Inst. 93: 691–699
Campbell SL, Khosravi-Far R, Rossman KL, Clark GJ, Der CJ . 1998 Oncogene 17: 1395–1413
Clark GJ, Drugan JK, Rossman KL, Carpenter JW, Rogers-Graham K, Fu H, Der CJ, Campbell SL . 1997 J. Biol. Chem. 272: 20990–20993
Crespo P, Leon J . 2000 Cell. Mol. Life Sci. 57: 1613–1636
Dammann R, Li C, Yoon JH, Chin PL, Bates S, Pfeifer GP . 2000 Nat. Genet. 25: 315–319
Dammann R, Takahashi T, Pfeifer GP . 2001a Oncogene 20: 3563–3567
Dammann R, Yang G, Pfeifer GP . 2001b Cancer Res. 61: 3105–3109
Dreijerink K, Braga E, Kuzmin I, Geil L, Duh FM, Angeloni D, Zbar B, Lerman MI, Stanbridge EJ, Minna JD, Protopopov A, Li J, Kashuba V, Klein G, Zabarovsky ER . 2001 Proc. Natl. Acad. Sci. USA 98: 7504–7509
Jones PA, Laird PW . 1999 Nature Genet. 21: 163–167
Katz ME, McCormick F . 1997 Curr. Opin. Genet. Dev. 7: 75–79
Khokhlatchev A, Rabizadeh S, Xavier R, Nedwidek M, Chen T, Zhang X-F, Seed B, Avruch J . 2002 Curr. Biol. in press
Kros JM, van Run PR, Alers JC, Beverloo HB, van den Bent MJ, Avezaat CJ, van Dekken H . 1999 J. Pathol. 188: 282–288
Lee MG, Kim HY, Byun DS, Lee SJ, Lee CH, Kim JI, Chang SG, Chi SG . 2001 Cancer Res. 61: 6688–6692
Lo K-W, Kwong J, Hui AB-Y, Chan SY-Y, To K-F, Chan AS-C, Chow LS-N, Teo PML, Johnson PJ, Huang DP . 2001 Cancer Res. 61: 3877–3881
Marshall CJ . 1996 Curr. Opin. Cell Biol. 8: 197–204
Newton AC . 1995 Curr. Biol. 5: 973–976
Ortiz-Vega S, Khokhlatchev A, Nedwidek M, Zhang X-F, Dammann R, Pfeifer GP, Avruch J . 2002 Oncogene in press
Petersen C, Orem N, Trueheart J, Thorner JW, Macara IG . 2000 J. Biol. Chem. 275: 4081–4091
Ponting CP, Benjamin DR . 1996 Trends Biochem. Sci. 21: 422–425
Reddy EP, Reynolds RK, Santos E, Barbacid M . 1982 Nature 300: 149–152
Ried T, Just KE, Holtgreve-Grez H, du Manoir S, Speicher MR, Schrock E, Latham C, Blegen H, Zetterberg A, Cremer T, Auer G . 1995 Cancer Res. 55: 5415–5423
Sekido Y, Ahmadian M, Wistuba II, Latif F, Bader S, Wei MH, Duh FM, Gazdar AF, Lerman MI, Minna JD . 1998 Oncogene 16: 3151–3157
Shields JM, Pruitt K, McFall A, Shaub A, Der CJ . 2000 Trends Cell Biol. 10: 147–154
Thompson JD, Higgins DG, Gibson TJ . 1994 Nucl. Acids Res. 22: 4673–4680
Vavvas D, Li X, Avruch J, Zhang X-F . 1998 J. Biol. Chem. 273: 5439–5442
Vos MD, Ellis CA, Bell A, Birrer MJ, Clark GJ . 2000 J. Biol. Chem. 275: 35669–35672
Wistuba II, Behrens C, Virmani AK, Mele G, Milchgrub S, Girard L, Fondon JW, Garner HR, McKay B, Latif F, Lerman MI, Lam S, Gazdar AF, Minna JD . 2000 Cancer Res. 60: 1949–1960
Wittinghofer A, Herrmann C . 1995 FEBS Lett. 369: 52–56
Wittinghofer A, Nassar N . 1996 Trends Biochem. Sci. 21: 488–491
Xiong Z, Laird PW . 1997 Nucl. Acids Res. 25: 2532–2534
Yoon J-H, Dammann R, Pfeifer GP . 2001 Int. J. Cancer 94: 212–217
Acknowledgements
We thank Steve Bates for tissue culture work. We thank Dr Lynette Grouse and Dr Narayan Bhat of NCI for provision of the human melanoma cell line and the mRNA used for the preparation of cDNA library NIH-MGC-20. This study was supported by a grant from the University of California Tobacco Related Disease Research Program (10-RT-0016) and by NIH grant CA88873 to GP Pfeifer.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tommasi, S., Dammann, R., Jin, SG. et al. RASSF3 and NORE1: identification and cloning of two human homologues of the putative tumor suppressor gene RASSF1. Oncogene 21, 2713–2720 (2002). https://doi.org/10.1038/sj.onc.1205365
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1205365
Keywords
This article is cited by
-
NORE1A directs apoptotic switch of TNF signaling through reciprocal modulation of ITCH-mediated destruction of TNFRI and BAX
Oncogene (2020)
-
Tumor suppressor C-RASSF proteins
Cellular and Molecular Life Sciences (2018)
-
RASSF5A, a candidate tumor suppressor, is epigenetically inactivated in esophageal squamous cell carcinoma
Clinical & Experimental Metastasis (2015)
-
NORE1A sensitises cancer cells to sorafenib-induced apoptosis and indicates hepatocellular carcinoma prognosis
Tumor Biology (2014)
-
RASSF10 Promoter Hypermethylation Is Frequent in Malignant Melanoma of the Skin but Uncommon in Nevus Cell Nevi
Journal of Investigative Dermatology (2012)